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Abstract
The mouse submandibular gland (SMG) epithelium undergoes extensive morphogenetic branching during embryonic development as the
first step in the establishment of its glandular structure. However, the specific signaling pathways required for SMG branching morpho-
genesis are not well understood. Using E13 mouse SMG organ cultures, we showed that inhibitors of phosphatidylinositol 3-kinase (PI
3-kinase), wortmannin and LY294002, substantially inhibited branching morphogenesis in SMG. Branching morphogenesis of epithelial
rudiments denuded of mesenchyme was inhibited similarly, indicating that PI 3-kinase inhibitors act directly on the epithelium. Immuno-
staining and Western analysis demonstrated that the p85 isoform of PI 3-kinase is expressed in epithelium at levels higher than in the
mesenchyme. A target of PI 3-kinase, Akt/protein kinase B (PKB), showed decreased phosphorylation at Ser473 by Western analysis in the
presence of PI 3-kinase inhibitors. The major lipid product of PI 3-kinase, phosphatidylinositol 3,4,5-trisphosphate (PIP3), was added
exogenously to SMG via a membrane-transporting carrier in the presence of PI 3-kinase inhibitors and was found to stimulate cleft
formation, the first step of branching morphogenesis. Together, these data indicate that PI 3-kinase plays a role in the regulation of epithelial
branching morphogenesis in mouse SMG acting through a PIP3 pathway.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The submandibular gland is a classical model for the
study of branching morphogenesis (Bernfield and Wessells,
1970; Grobstein and Cohen, 1965; Spooner and Wessells,
1972). During development, the submandibular gland ini-
tiates as a protrusion of the oral epithelium into the sur-
rounding mesenchyme. The first step of branching morpho-
genesis is cleft formation, in which visible clefts, or
indentations, form in the surface of the single bud. It is not
known whether there is a signal to specify the location of
the cleft, although there is some evidence that a stabilization
event is required (Hieda and Nakanishi, 1997; Miyazaki,
1990). The clefts then deepen, to separate the single bud
into multiple buds, until there is presumably a termination
signal. This sequence of events then repeats and is known
collectively as the process of branching morphogenesis.
Although proliferation is ultimately required for gland
growth, and later morphogenesis, early branching is not
dependent on cell proliferation (Nakanishi et al., 1987;
Spooner et al., 1989). Branching is instead dependent on
multiple processes, such as cell–cell interactions, cell–ma-
trix interactions, matrix degradation, and cell-shape changes
(Hieda and Nakanishi, 1997).
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Growth factors provide a driving force for many cellular
processes. The two major growth factor families that have
been implicated in the control of branching morphogenesis
are the epidermal growth factor (EGF) (Kashimata and
Gresik, 1997; Morita and Nogawa, 1999; Partanen and
Thesleff, 1987) and the fibroblast growth factor (FGF) fam-
ilies (Hoffman et al., 2002). The involvement of EGFR1 in
branching morphogenesis was confirmed by the observation
that the EGFR1 null mouse showed reduced branching
within the salivary gland epithelium (Jaskoll and Melnick,
1999). Using an inhibitor approach to study EGF signaling
in the salivary gland, it was shown that inhibition of Erk1/2
(p44/p42 MAPK) signaling partially inhibits EGF-stimu-
lated branching morphogenesis (Kashimata et al., 2000),
suggesting that this signaling pathway participates in
branching morphogenesis. The FGF family has also been
implicated in early mouse submandibular gland develop-
ment. The FGFR2IIIb-null mouse lacks salivary glands, as
they undergo agenesis prior to initiation of branching mor-
phogenesis (De Moerlooze et al., 2000; Sekine et al., 1999),
and the FGF10-null mouse displays a similar phenotype
(Ohuchi et al., 2000; Sekine et al., 1999). FGFR1 inhibitor
SU5402 limits SMG branching morphogenesis in organ
culture (Hoffman et al., 2002). The integrin family of ex-
tracellular matrix adhesion molecules plays a role in branch-
ing morphogenesis as well. In organ culture, anti-integrin
6 antibodies inhibit branching morphogenesis (Kadoya
and Yamashina, 1993; Kadoya et al., 1995), and EGF can
regulate integrin 6 expression in SMG (Kashimata and
Gresik, 1997), which implicates integrin 6 pathways in
EGF-stimulated branching morphogenesis. However, with
the exception of Erk1/2, none of the intracellular signaling
molecules necessary for branching morphogenesis have
been identified.
Organ culture systems present a valuable intermediate
between cell culture and in vivo studies that facilitates the
study of developmental processes requiring tissue organiza-
tion. To identify molecules involved in signaling during
SMG branching morphogenesis, we utilized a chemical
inhibitor screening approach in an organ culture system.
While the gene profiling technique of array analysis has
recently been applied to developing salivary glands, very
few intracellular signaling molecules have been identi-
fied with this approach (Hoffman et al., 2002; Melnick
et al., 2001) since genes of low abundance or high turn-
over are below the limits of detection. Additionally,
gene profiling techniques cannot identify posttranslational
events such as phosphorylation. However, using chemi-
cal inhibitors in a morphological assay, it is possible to
interrupt signal transduction pathways and to ascertain
whether specific molecules affect the process of branching
morphogenesis.
In this study, we found that inhibitors of phosphoinosi-
tide 3-kinase (PI 3-kinase) inhibit branching morphogene-
sis. We also report that PI 3-kinase inhibitors act directly on
the epithelium and that phosphatidylinositol 3,4,5-trisphos-
phate (PIP3), the downstream product of PI 3-kinase, can
stimulate cleft formation. These data indicate that a PI
3-kinase pathway in which PIP3 formation is stimulated is
involved in branching morphogenesis during submandibular
gland development.
Materials and methods
In vitro organ culture
Timed-pregnant female mice (strain ICR) were obtained
from Harlan (Indianapolis, IN), and embryos were removed
at 12 dpc (embryonic day 12, or E12, which was prior to
initiation of branching) or at 13 dpc (E13, after the initial
round of branching). SMG at E13 in this mouse strain can
be developmentally considered to be between the “late ini-
tial bud” and “pseudoglandular” stage described previously
(Jaskoll et al., 2002). The epithelial SMG structures that
undergo clefting have been referred to in the literature as
“early terminal end buds,” “end pieces,” “lobules,” and
“buds;” in this manuscript, we have referred to these struc-
tures simply as “buds.”
Mandible sections were isolated with a scalpel, and sub-
mandibular glands with attached sublingual glands (here-
after referred to as SMG) were removed from these sec-
tions under a dissecting microscope (SV6, Carl Zeiss,
Oberkochen, Germany). The SMG were cultured on mem-
branes at the air/medium interface at 37°C for 1–72 h. Five
or more glands were placed on Nuclepore Track-Etch Mem-
branes (Whatman, Clifton, NJ) (13 mm, 0.1 M) floating on
250 L of DMFTV standard media [DMEM/F12 (1:1)
(Invitrogen, Carlsbad, CA) supplemented with transferrin
(1.25 g/ml), ascorbic acid (3.75 g/ml), penicillin (10
U/ml), and streptomycin (10 g/ml)] in glass-bottom
50-mm microwell dishes (MatTek Corp, Ashland, MA).
SMG were kept on ice until the inhibitors were added (time
0) and then were cultured at 37°C, 5% CO2 in a humid
atmosphere for the indicated times. Media were generally
replaced every 24 h.
For mesenchyme-free experiments, SMG were digested
with 1.6 U/ml dispase (Roche, Basel, Switzerland) in
Hanks’ salt solution (Invitrogen) at 37°C for 20 min and
neutralized with DMEM/F12  5% BSA, and mesenchyme
was removed from epithelium using tungsten needles (Ta-
kahashi and Nogawa, 1991). Epithelial rudiments were cul-
tured on filters in 20 l of 12 mg/ml Matrigel (BD Bio-
sciences, San Jose, CA) (Royce et al., 1993) in the presence
of 20 ng/ml EGF and 200 ng/ml FGF7, as described previ-
ously (Morita and Nogawa, 1999). In the absence of exog-
enous growth factors, the epithelial rudiments do not grow
or branch (data not shown). Mesenchyme-free experiments
included a minimum of three SMG per condition and were
repeated at least three times.
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Branching morphogenesis assays
Signal transduction inhibitors (Calbiochem, San Diego,
CA, or Sigma-Aldrich, St. Louis, MO) were resuspended in
DMSO, 50% ethanol, or DMEM-F12 media, depending on
their solubility, and included in regular culture media at the
concentrations indicated. For each experiment, at least five
E13 SMG were used for each treatment, and at least three
concentrations of each inhibitor were tested. Inhibitors were
assayed at concentrations near their published IC50 values at
subtoxic levels. Toxicity was recognized as an apparent
darkening of the epithelial cells when imaged by brightfield
microscopy and was defined operationally as a state at
which the SMG would not resume proliferation after 24 h if
the inhibitor-containing media were replaced with fresh
media. The following compounds were found to be toxic in
this system at these levels: herbimycin A, 1 M; genistein,
250 M; lavendustin, 500 M; okadaic acid, 1 M; and
apigenin, 50 M. Control media contained vehicle at the
same concentration as was included with the inhibitor.
DMSO concentrations did not exceed 0.2% v/v for any
treatment and did not affect submandibular gland growth or
morphology at this concentration. Inhibitor-containing me-
dia were replaced in all experiments at 24 h. Inhibitors were
stored as recommended by the manufacturer and, when
necessary, reconstituted immediately prior to the experi-
ment.
Photographs were taken at 2, 22, and 44 h with a digital
SLR camera (Fuji FinePix, Fuji, Tokyo, Japan) fitted on an
Axiovert 25 microscope (Carl Zeiss), unless otherwise in-
dicated. Initial photographs were taken 2 h after placing the
cultures in the incubator; at this time, SMG have spread on
the filter but have not yet started branching. The total num-
ber of buds per salivary gland were counted manually using
a blinded procedure with predefined criteria, and the data
were tabulated automatically by MetaMorph (Universal Im-
aging, Downingtown, PA; V4.6). Data were imported into
GraphPad Prism software (V3.0a, San Diego, CA) for
graphing and statistical analysis. For each treatment, the
growth at each time point was assessed by dividing the
number of buds by the starting number for each SMG
individually, averaging these values, and expressing the
results as fold change buds/gland in arbitrary units (AU).
For the inhibitor screen and experiments in which multiple
treatments were compared, average values for each treat-
ment were normalized to control and expressed as a per-
centage of control. Results of the inhibitor screen are ex-
pressed as percent of control in AU from a representative
experiment using five glands per treatment; each experiment
was repeated at least once. The results reported in Table 1
were measured at the lowest concentration that produced
maximum inhibition and did not result in toxicity after 24 h.
Statistical analysis was performed as indicated in the
figures and text. For the inhibitor screen, the significance of
the difference between the treatment reported and the con-
trol was determined by unpaired, two-tailed t test, assuming
equal variance within each experiment, although the vari-
ance was different between experiments. One-way analysis
of variance (ANOVA), was performed to determine the
statistical difference between the means of each treatment
for experiments in which multiple treatments were com-
pared. The conservative Bonferroni’s Multiple Comparison
Post-Test was combined with the ANOVA in order to com-
pare differences between the means within an experiment.
For branching morphogenesis assays in which two in-
hibitors were combined, both were added at their approxi-
mate IC50 values for this organ culture system. The IC50 for
each inhibitor was estimated from a previous independent
dose-response experiment. Combination experiments were
repeated at least three times, although data shown are from
one representative experiment.
Time-lapse microscopy
SMG were precultured in microwell dishes on Nuclepore
filters for 2 h in the presence of 20 M LY or control media.
For time-lapse microscopy, E13 SMG were incubated at
37°C with 5% CO2 and humidified air in an environmental
chamber fitted on a Nikon Diaphot inverted microscope and
imaged with a cooled CCD camera (Photometrics CH320;
Roper Scientific, Trenton, NJ) or on an Axiovert 100 in-
verted microscope (Carl Zeiss) fitted with a cooled CCD
camera (MicroMAX: 1300Y; Princeton Instruments, Mon-
mouth Junction, NJ). Images were acquired using bright-
field optics through a 5 objective once every 10 min for
20 h using MetaMorph Software. Images were adjusted for
brightness, contrast, and alignment, as necessary, and were
assembled into movies using MetaMorph.
Cleft formation assays
For cleft formation assays, PtdIns(3,4,5)P3 diC16 (PIP3)
was added to E13 SMG cultures via the Shuttle PIP system
(Echelon Research Laboratories, Salt Lake City, UT). PIP3
was mixed with carrier 1 (C1, neomycin sulfate) at a con-
centration of 50 M for each, and complexes were allowed
to form for 10 min at room temperature (RT). The PIP3-C1
complex was added to prewarmed SMG DMFTV media and
then added to cultures. Uptake of PIP3 by the SMG during
culture was initially confirmed by using a fluorescent con-
focal microscope (LSM510, Zeiss) to observe NBD-labeled
PIP3 (PIP3-C6NBD, C16) in both the epithelium and mes-
enchyme of whole-mount SMG fixed with 3% paraformal-
dehyde in 1  PBS for 15 min at RT, 10 min after addition
of labeled PIP3 to the culture media. Cleft-forming assays
were performed using unlabeled PIP3. For cleft formation
assays, SMG were harvested as described, except that 5–12
SMG were set up on filters in ordered pairs such that pairs
from the same embryo were compared  PIP3. Addition-
ally, they were maintained at RT until addition of PIP3-C1
or C1, after which they were cultured under normal condi-
tions. PIP3-C1 or C1 was added once per hour by replacing
180 M. Larsen et al. / Developmental Biology 255 (2003) 178–191
the entire growth media. SMG were digitally photographed
at 2 and 8 h. The numbers of clefts present at the surface of
the epithelium were counted from digital images, tabulated
in MetaMorph, and graphed using Prism software, as de-
scribed for branching morphogenesis assays. Statistical
analysis of PIP3 experiments was performed using paired,
two-tailed t tests. Cleft formation assays were repeated three
or more times with data shown from a representative ex-
periment.
Immunofluorescence
E13 SMG were grown in organ culture for 24 h and fixed
overnight at 4°C in 4% paraformaldehyde, 5% sucrose in
1 PBS. Fixed SMG were permeabilized and blocked in
1 PBS, 0.1% Triton X-100, 20% donkey serum, and
Mouse on Mouse (M.O.M.) blocking reagent (Vector Lab-
oratories, Burlingame, CA), as recommended by the man-
ufacturer. SMG were incubated in primary antibody in di-
luent (1 PBS, 0.01% Triton X-100, containing 7% protein
concentrate) (M.O.M. kit; Vector Laboratories) overnight at
4°C, and then with secondary antibody for 1 h at RT in
diluent. SMG were washed 3  10 min in 1  PBS con-
taining 0.05% Tween 20 after each antibody incubation.
Immunostaining was repeated at least three times.
Antibody concentrations and sources were as follows: PI
3-kinase, p85 1:100 (06-497; UBI, Watham, MA); rhoda-
mine phalloidin, 1:350 (Molecular Probes, Eugene, OR);
and anti-heparan sulfate proteoglycan (perlecan), 1:100
(MAB1948; Chemicon, Temecula, CA). Secondary anti-
bodies for indirect immunofluorescence were cyanine dye-
conjugated AffiniPure F(ab)2 fragment donkey anti-mouse
or -rabbit IgG (H  L), showing minimal cross-reactivity
with serum proteins from multiple species (Jackson Immu-
noResearch Laboratories, West Grove, PA).
Western analysis
SMG were grown in culture in the presence of inhibitors
or vehicle control for the time periods indicated. For prep-
aration of epithelial- or mesenchyme-enriched extracts, the
cell types were enzymatically and physically separated as
described in Materials and methods under “In vitro organ
culture.” Whole E13 SMG, epithelium, or mesenchyme
were placed in a microfuge tube and were either immedi-
ately frozen in a dry ice/methanol bath and stored at 80°C
Table 1
Effects of cell signaling modulators on salivary gland branching morphogenesis (E13)
Inhibitor Potential targets Concentration (M) Buds/gland
% of control  SEM
Range Optimala 22 h 44 h
Receptor tyrosine kinases
Herbimycin A Protein tyrosine kinases 0.1–1 0.5 64  9* NDb
Genistein Protein tyrosine kinases 0.25–250 2.5 52  14c 9  7c
Lavendustin Protein kinases 10–50 50 82  13 61 4*
ST638 Tyrosine kinases, HGFR, phospholipase D 50–100 100 94  10 ND
AG1433 PDGFR, KDR/Flk-1 50 50 66  7 ND
Phosphatases
Okadaic acid Protein phosphatases PP2A, PP1, PP2B 0.050–0.100 0.1 56 25 62 15
Calyculin A Phosphatases PP2A, PP1 0.001–20 0.1 78  20 56 9†
Vanadate Tyrosine-phosphatases, Na/K ATPase,
acid and alkaline phosphatases
0.4–200 40 79  5 40 6*
Cytoplasmic kinases/other
KN-62 Calmodulin-dependent protein kinase 2 1–20 10 113  18 102  14
KN-93 Calmodulin-dependent protein kinase 2 0.5–1 1 98  22 ND
SKF86002 p38, cycloxygenase, 5-lipoxygenase 1–20 20 110  12 134  22
ZM336372 cRaf, p38, p382 0.02–2 2 101  22 132  25
Apigenin CK2, MAPK, PKC, FGFR 25–50 40 79  9 64 15*
Rapamycin p70S6K, mTOR 0.0001–10 5 104  7 111  8
Staurosporin PKC, MLCK, PKA, PKG, CaMK 0.001–0.020 20 87 12d 96  9d
Lysophosphatidic acid Activates PKC, adenyl cyclase, G
proteins, tyrosine kinases, MAPK
5–50 50 92  20 113 12
LY294002 PI 3-kinase 0.5–50 25 22  4* 13 3*
Wortmannin PI 3-kinase 0.001–0.100 0.01 56 16† 50  14*
Note. The number of lobules/rudiment for each treatment was counted at 22 and 44 h and normalized to control. Values are derived from a representative
experiment, n  5.
a Concentration used to obtain data reported for 22 and 44 h, see Materials and methods.
b Not done.
c Quantitated using E12 SMG.
d Reduced bud size.
* P  0.05; † P  0.1 by unpaired, two-tailed t test assuming equal variance.
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or solubilized in complete RIPA buffer (150 mM NaCl, 50
mM Tris-HCl, pH 7.5, 1% Triton X-100, 1% sodium de-
oxycholate, 0.1% SDS, 1 mM sodium vanadate, 1 mM
sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 1
mM EDTA, containing one complete mini protease inhibi-
tor tablet (Roche) per 10 ml buffer). SMG in RIPA buffer
were sonicated on ice at an amplitude of 40 for 10 s by using
a probe sonicator, and the insoluble fraction was removed
by centrifugation at 14,000 g at 4°C for 20 min. Protein
concentrations were assayed using the Micro BCA protein
assay (Pierce, Rockford, IL), and 5 or 10 g of protein were
loaded per lane on a 1.5-mm 4–12% SDS-PAGE gel (In-
vitrogen). Proteins were transferred to nitrocellulose and
stained with Ponceau to confirm transfer efficiency. Mem-
branes were blocked for 1 h in 5% nonfat milk in 1 TBS-T
(Tris-buffered saline, 0.1% Tween 20) and incubated with
primary antibody overnight at 4°C with 1% milk in 1
TBS-T, and secondary antibody for 1 h at RT in 1% milk,
1 TBS-T. Blots were washed after each antibody incuba-
tion in 1 TBS-T three times for 10 min. Blots were
developed using a chemiluminescent development solution
(Super Signal West Dura; Pierce) and analyzed with a Fuji
LAS-100 chemiluminescent imager using exposure times at
subsaturation levels. Blots were quantitated by using Image
Gauge (V3.3) (Fuji) in profile mode, utilizing background
subtraction and integration of pixel density within each
band area. Pixel density for each band was normalized to
actin for each lane to control for any loading error. Graphs
were compiled in Prism, and results are shown in arbitrary
units (AU). Each blot was repeated two to three times and
each experiment repeated two to three times. Blots shown
are representative, and the graphs were generated from the
blots shown.
Antibodies obtained from the sources indicated were
used at the following concentrations: PI 3-kinase p85,
1:4000 (06-497; UBI); Akt, 1:2500 (9272; Cell Signaling,
Beverly, MA); phospho-Akt (Ser473), 1:2500 (9271S; Cell
Signaling); -actin, 1:10,000 (clone AC-74; Sigma); E-
cadherin, 1:5000 (610181; BD Transduction); and vimentin
1:5000 (clone 13.2; Sigma). The secondary antibodies used
were HRP-conjugated donkey anti-rabbit or -mouse immu-
noglobulin (Amersham-Pharmacia, Piscataway, NJ) and
were used at 1:10,000.
Results
PI 3-kinase inhibitors affect salivary gland branching
morphogenesis
In order to identify candidate signal transduction path-
ways required for branching morphogenesis during SMG
development, we utilized an inhibitor screening strategy.
We harvested submandibular glands from mouse embryos
after a single round of branching (E13) and grew them in
organ culture. To the culture media, we added signal trans-
duction inhibitors and monitored gland branching in the
presence of the inhibitors in comparison with control SMG.
At 22 and 44 h, we photographed each SMG and then
counted the number of buds per gland, as described in
Materials and methods. The results of this initial inhibitor
screen are summarized in Table 1.
We found that a number of inhibitors did not affect
branching morphogenesis, while a few inhibited branching
in a statistically significant manner. Not surprisingly, global
inhibitors of receptor tyrosine kinases, including herbimy-
cin, genistein, and lavendustin, significantly inhibited
branching morphogenesis, yet these inhibitors do not iden-
tify a specific pathway. The phosphatase inhibitors, which
might be expected to oppose kinase action, actually inhib-
ited branching morphogenesis over a range of concentra-
tions. Of the cytoplasmic kinase inhibitors tested, few
showed significant effects. However, apigenin, an inhibitor
of multiple kinases, showed a moderate inhibition of
branching morphogenesis at high concentrations. Several
inhibitors examined in this study showed minor effects on
branching morphogenesis, yet these effects were not statis-
tically significant.
In contrast, inhibitors of phosphatidylinositol 3-kinase
(PI 3-kinase) had major effects on branching morphogenesis
(Table 1); consequently, we focused on testing the role of
the PI 3-kinase pathway. Fig. 1A shows time-lapse micros-
copy (see Movie 1 at http://wwwdir.nidcr.nih.gov/dirweb/
cdbrb/DMD/larsen/DB/movies.asp) of a control SMG and a
SMG treated with the PI 3-kinase inhibitor LY294002 (LY)
at 20 M. While the control gland undergoes multiple
rounds of branching during the 20-h time period, the LY-
treated gland undergoes only one round of branching. In the
LY-treated SMG, the buds enlarge more than in control-
treated glands prior to the initiation of clefting, and the
process of cleft formation itself is slower, indicating that LY
inhibits cleft formation—the initial step in SMG branching
morphogenesis. The inhibition of branching morphogenesis
by LY is generally consistent with a recent report in which
LY was found to limit branching morphogenesis in the
ureteric bud epithelium (Tang et al., 2002). However, in the
kidney, PI 3-kinase is implicated in inhibiting ureteric bud
outgrowth, rather than in cleft formation, which does not
occur during ureteric branching.
The effects and specificity of the PI 3-kinase inhibitors
were analyzed quantitatively by comparing the effects of
two structurally distinct PI 3-kinase inhibitors: LY, which
acts on the ATP-binding site, and wortmannin (wmn), a
fungal metabolite that covalently binds PI 3-kinase and
irreversibly blocks catalytic activity. Both LY (Fig. 1B) and
wmn (Fig. 1C) effectively inhibited branching morphogen-
esis in E13 glands in a dose-dependent manner. We found
that the IC50 values for LY and wmn in E13 SMG were
approximately 4 M and 4 nM, respectively, whereas the
reported IC50 of LY is 1.4 M and of wmn in purified
cytosolic preparations is 5 nM. Therefore, the dose-depen-
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dent effectiveness of the PI 3-kinase inhibitors in SMG
organ cultures was comparable to reported values.
In order to confirm that the inhibition by LY was non-
toxic and reversible, we treated the glands with the inhibitor
for 24 h, washed out the inhibitor at 24 h, and then exam-
ined the glands at 68 h (Fig. 1D–I). The effects of LY were
Fig. 1. Inhibitors of PI 3-kinase inhibit salivary gland branching morphogenesis in organ culture. (A) E13 SMG were treated with 20 M LY294002 or control
media and observed with time-lapse microscopy for 20 h. Shown are the first and last images of control- and LY-treated SMG (see http://wwwdir.nidcr.
nih.gov/dirweb/cdbrb/DMD/larsen/DB/movies.asp for Movie 1). There is a significant inhibition of SMG branching in the presence of 20 M LY294002
relative to control glands at 20 h. (B, C) The PI 3-kinase inhibitors LY and wortmannin (wmn) were added to SMG organ cultures at increasing concentrations.
Dose-response of LY (B) and wmn (C) in E13 SMG cultures show the number of buds per gland on the y-axis. Effects of LY on SMG branching can be
reversed upon removal of inhibitor from the growth media. Shown are SMG at 24 h: control (D), 10 M LY (E), and 50 nM wmn (F). After 68 h, the control
glands (G) have continued branching, and SMG treated with LY (H) remain inhibited. (I) SMG treated with LY for 24 h and then switched to control media
(LY-wash) have resumed branching. (J) Quantitation of inhibition with 10 M LY at 24 h and recovery of SMG after removal of LY from the media, graphed
as buds/gland, normalized to the number of buds per gland at 2 h, and expressed in arbitrary units (AU) vs time. Differences between all samples (except
LY and LY-wash at 24 h) were significant by one-way ANOVA at P  0.05, and the difference between LY and LY-wash at 68 h was significant at P 
0.0001 by unpaired, two-tailed t test, assuming equal variance. Scale bars, 100 m.
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fully reversible. Statistical significance of inhibition by LY
was calculated for the washout experiment (Fig. 1D–I) and
was found to be significant at P  0.05 for 24 and 68 h by
one-way ANOVA, as indicated in Fig. 1J. The difference
between treatment with LY and the washout of LY was
significant at P  0.0001 by t test at 44 h after the removal
of the inhibitor. Together, these data indicate that PI 3-ki-
nase inhibitors substantially inhibit SMG branching mor-
phogenesis, thereby indicating that PI 3-kinase is involved
in salivary gland branching morphogenesis.
Inhibitors inhibit cleft formation and branching in the
absence of mesenchyme
Since epithelial–mesenchymal interactions are impli-
cated in SMG branching morphogenesis (Gilbert, 2000), we
asked whether the PI 3-kinase inhibitors acted directly on
the epithelium. We enzymatically and physically removed
the mesenchyme from E13 epithelial rudiments and cultured
the isolated epithelia in Matrigel (Royce et al., 1993), a
basement membrane extract, in the presence of EGF and
FGF7, which were previously shown to support growth and
branching of submandibular gland rudiments in the absence
of mesenchyme (Morita and Nogawa, 1999). Without mes-
enchyme, both LY294002 and wortmannin inhibited cleft
formation and branching of submandibular epithelial rudi-
ments (Fig. 2C and D, respectively) relative to the control
(Fig. 2B) at 48 h. These data indicate that PI 3-kinase
inhibitors act directly on the epithelium and that PI 3-kinase
signaling in the mesenchyme may not be required for SMG
branching morphogenesis.
PI 3-kinase is localized in embryonic salivary gland
epithelium
The canonical class I PI 3-kinase is composed of a
regulatory subunit and a catalytic p110 subunit, with the
regulatory subunit necessary for targeting the catalytic sub-
unit to the membrane via receptor tyrosine kinases and/or
adapter molecules. The molecular targets of both LY and
wmn include both class I and class II PI 3-kinases. While
the IC50 values for the class I molecules are approximately
1 nM for wmn and 1 m for LY, for the class II molecules,
they are 50–450 nM and 19 M for wmn and LY, respec-
tively (Fruman et al., 1998), indicating that, in this series of
experiments, we are affecting primarily the class I PI 3-ki-
nases. The regulatory subunit of the class I PI 3-kinases
exists as two p85 isoforms,  and , which are relatively
similar, as well as a p55 isoform and two splice variants of
the p85. To confirm that PI 3-kinase is expressed in em-
bryonic mouse salivary gland, we performed Western im-
munoblot analysis of total cell extracts from both E13 and
E12 rudiments using an antibody recognizing both p85
isoforms as well as splice variants of the PI 3-kinase regu-
latory subunit. We detected a band of 85 kDa in both cell
extracts (Fig. 3A), indicating PI 3-kinase is present at both
prebranching and branching stages. To identify the tissue
localization of PI 3-kinase, we performed immunostaining
on whole-mount E13 rudiments and examined the expres-
sion pattern of the p85 subunit of PI 3-kinase by confocal
microscopy. We compared the staining pattern of PI 3-ki-
nase (Fig. 3B) with that of an anti-perlecan antibody (Fig.
3C) that recognizes the basement membrane so that we
could distinguish between epithelium and mesenchyme. We
also examined the staining pattern of phalloidin, which
binds actin (Fig. 3D), as a control for tissue penetration. We
detected PI 3-kinase in both the epithelium and mesen-
chyme, but levels were higher in the epithelium. The local-
ization pattern was virtually identical to that obtained using
a monoclonal PI 3-kinase p85 antibody (clone 4; BD Bio-
sciences-Transduction) (data not shown).
To confirm the preferential epithelial localization of PI
3-kinase, we physically separated the mesenchyme from the
epithelium of E13 SMG, made cell extracts from each
preparation, and compared the amounts of PI 3-kinase de-
tectable in the epithelium-and mesenchyme-enriched ex-
tracts by Western blot analysis (Fig. 4A). The epithelial
marker E-cadherin and the mesenchymal marker vimentin
confirmed the effectiveness of the cell separation technique.
Western analysis of the epithelial and mesenchymal cells
confirmed the preferential expression of the p85 subunit in
the epithelium (Fig. 4A). RT-PCR using cDNA prepared
Fig. 2. PI 3-kinase inhibitors inhibit branching morphogenesis in SMG
cultures denuded of mesenchyme. (A) E13 SMG were isolated, and mes-
enchyme was enzymatically and physically removed. (B) SMG lacking
mesenchyme cultured in Matrigel for 48 h with media containing 20 ng/ml
EGF and 200 ng/ml FGF7 undergo branching morphogenesis. (C, D) SMG
epithelial rudiments grown in Matrigel with media containing EGF and
FGF7 in the presence of PI 3-kinase inhibitors for 48 h show reduced
branching: 20 M LY (C), and 50 nM wmn (D), suggesting that PI
3-kinase inhibitors act directly on the epithelium. Scale bar, 100 m.
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from RNA from the epithelial and mesenchymal compart-
ments likewise indicated that PI 3-kinase mRNA is ex-
pressed 2.5-fold higher in the epithelium than in the mes-
enchyme (data not shown).
Akt is expressed in both epithelium and mesenchyme, and
dephosphorylation of Akt at Ser473 is detected in the
presence of LY294002
Since a major indirect target of PI 3-kinase in most cell
types is the Ser/Thr kinase Akt/PKB (protein kinase B), we
examined expression of Akt by Western analysis on the
epithelial- and mesenchymal-enriched extracts (Fig. 4A)
and quantitated these results (Fig. 4B). Akt was detectable
in both epithelium and mesenchyme at equivalent levels. To
confirm the expression pattern of Akt, we immunostained
whole-mount developing salivary glands and examined
them by confocal microscopy. In confirmation of the West-
ern analysis, we found Akt expression detectable in both
epithelium and mesenchyme (data not shown).
Regulation of the activity is complex and involves trans-
location to Akt membrane, which can be induced by PIP3
(Stephens et al., 1998), which is followed by phosphoryla-
tion at Thr308 and Ser473. Phosphorylation at Thr308 is me-
diated by phosphotidylinositol-dependent protein kinase 1
(PDK1) in response to PI 3-kinase activation. While the
source of phosphorylation at Ser473 is not known, it is the
site that must be phosphorylated for activation (For review,
see Scheid and Woodgett, 2001). To determine whether PI
3-kinase inhibitors affect the phosphorylation status, and
therefore the activity, of Akt, we harvested total salivary
gland extracts and examined Akt phosphorylation by West-
ern blotting. As shown in Fig. 4C, and quantitated in Fig.
4D, we found that the level of Akt phosphorylation at Ser473
was suppressed by inhibition of PI 3-kinase in a time-
dependent manner. From 1.5 to 7 h, there was increasing
inhibition of Akt phosphorylation (Fig. 4D). Although after
24 h in the presence of the LY294002 inhibitor, pAkt was
still substantially suppressed (data not shown), the levels
were further decreased following addition of new inhibitor
at 24 h, as shown in Fig. 4D (total time, 25 h). Additionally,
we localized the activated phosphorylated form of Akt,
pAkt (Ser473), which was detectable in both the epithelium
and mesenchyme, but was not detectable in SMG treated
with LY for 3 h (data not shown). These findings confirm
that the PI 3-kinase inhibitor effectively penetrated into the
epithelium. Further, these data indicate that inactivation of
Akt correlates with inhibition of PI 3-kinase during SMG
development and suggest that Akt may play a role in
branching morphogenesis.
PIP3 stimulates branching
To determine whether modulation of a downstream ef-
fector of PI 3-kinase affects branching morphogenesis, we
used the lipid PIP3, formed as a result of a phosphorylation
of PIP2 at its 3 position by PI 3-kinase. To confirm that
PIP3 was able to penetrate into the SMG, we examined the
distribution of a fluorescently labeled form of PIP3 coupled
to a membrane carrier. PIP3 was detected in both the epi-
thelial and mesenchymal compartments after 10 min (data
not shown). In order to determine whether the SMG could
be rescued from the inhibitory effects of PI 3-kinase inhib-
itors by the addition of PIP3 to the system, we added
nonlabeled PIP3 at 1-h intervals and examined the SMG
morphology at 8 h. The short half-life of PIP3 necessitated
the hourly addition of PIP3. Since we assayed for effects of
PIP3 at a time point during branching and prior to comple-
tion of a cycle, we assayed cleft, rather than bud, formation.
We found that, in the presence of LY294002 (20 M), a
Fig. 3. PI 3-kinase is expressed in embryonic SMG. (A) Extracts from E12
and E13 SMG were probed with an antibody recognizing the p85 isoform
of PI 3-kinase, and a band of apparent molecular weight 85 kDa was
observed in both extracts. E13 SMG were fixed, immunostained, and
examined by confocal microscopy. Shown is a single section of a single
bud labeled with: (B) anti-p85 antibody, (C) the basement membrane
marker perlecan, and (D) rhodamine-phalloidin that binds actin filaments
and demonstrates effective penetration of labeled molecules. (E) Merge of
three channels. PI 3-kinase was primarily localized in the epithelium (e)
with some localization in the mesenchyme (m). Scale bar, 20 m.
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significant decrease in cleft number was detectable relative
to control (P  0.05; Fig. 5E). In the presence of 10 M
LY, PIP3 stimulated cleft formation (Fig. 5B) relative to
control (Fig. 5A), as can be seen in the higher magnification
view of Fig. 5B in Fig. 5D relative to its pair in Fig. 5C.
When this experiment was quantitated (Fig. 5E), it was
found that PIP3-stimulated cleft formation was statistically
significant relative to control in the presence of 5 M LY.
These data indicate that PIP3 may be involved in stimulation
of cleft formation during branching morphogenesis.
PI3-kinase signaling is partially independent of known
pathways
We wished to determine whether the PI 3-kinase-medi-
ated pathway that we have identified is part of or is inde-
pendent of the pathways currently known to be involved in
SMG branching morphogenesis. We performed branching
assays using LY in combination with other signal transduc-
tion inhibitors. When a maximal dose of LY (10 M; Fig.
6B) was compared with a maximal dose of the Erk1/2
inhibitor PD98059 (50 M; Fig. 6C), the inhibition of
branching by LY was more significant. When maximal
doses of LY and PD were combined, there was no signifi-
cant increase in the inhibition provided by LY alone (Fig.
6D). When this combination experiment was quantitated
and the statistical significance evaluated by one-way
ANOVA (Fig. 6E), the values were found to be significantly
different (P  0.0001). The effects of LY and PD98059
were both significantly different from control and from each
other (P  0.0001), while the difference between LY and
LY  PD98059 was not (P  0.05; Fig. 6B), as determined
by Bonferroni’s Multiple Comparison Post-Test. We also
combined LY and PD at concentrations near their IC50
levels and found the same result (data not shown). These
data show that, while the effects of LY on branching mor-
phogenesis are larger than the effects of the Erk 1/2 inhib-
itor, there is not an additive effect, indicating that PI 3-ki-
nase may be acting as part of the same pathway as Erk1/2.
Since Erk1/2 have been shown to act downstream of
EGF signaling, we compared the effects of LY with that of
an EGF receptor (EGFR) inhibitor. We added LY at its
approximate IC50 value for this system (5 M; Fig. 6B) and
compared it with a maximal dose of a specific EGFR in-
Fig. 4. Western analysis of PI 3-kinase and downstream target Akt in E13 SMG. (A) Epithelium (E)- and mesenchyme (M)-enriched cell extracts were
generated and analyzed by Western analysis. The epithelial marker E-cadherin and the mesenchymal marker vimentin were used to confirm the effectiveness
of the separation. In agreement with immunolocalization, PI 3-kinase was expressed primarily in the epithelium, while Akt was in both cellular compartments.
(B) Quantitation of the Western analysis in (A), graphed as the relative pixel density of each band relative to the actin control for each lane. (C) Whole SMG
were treated with LY (25 M) or wmn (50 nM) for 1.5, 3, 7, or 25 h. Extracts were analyzed by Western analysis with anti-pAkt (Ser473), Akt, and actin
antibodies on blots that were stripped and reprobed. (D) Quantitation of the Western blot in (C), graphed as the relative pixel density of each band relative
to the actin controls for each lane and normalized to control at each time point, indicates that the level of phosphorylation of Akt at Ser473 correlates with
increasing time of incubation with LY. Treatment with wmn shows a similar effect at 25 h and at 1.5–7 h (data not shown).
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hibitor, PD153035 (50 pM; Fig. 6F). Again, the effect of LY
was larger than the effect of the EGFR inhibitor, and when
the two inhibitors were combined at these concentrations,
the effects were not additive (Fig. 6G). The quantitation and
statistical analysis of this experiment, shown in Fig. 6H,
indicated that the means are significant by ANOVA (P 
0.05). However, there was no significant difference between
LY alone and LY  PD153035. The same result was found
when combining LY with larger doses of PD153035 as well
as with other inhibitors of EGFR, including PD168393,
PD156273, and the tyrophostin AG 1478 (data not shown).
These results are consistent with the hypothesis that PI
3-kinase signaling is a component of the EGFR mediated
pathway.
Because the effects of the PI 3-kinase inhibitor on SMG
branching morphogenesis are larger than that of either the
EGFR or the Erk inhibitor, we questioned whether PI 3-ki-
nase could be a component of more than one signaling
pathway. Recently, the FGFR inhibitor SU5402 (SU) was
found to inhibit branching morphogenesis (Hoffman et al.,
2002). We added SU at a concentration close to its IC50 in
this system (2 M; Fig. 6I) and found that it appeared to
limit the process of branching morphogenesis but also af-
fected the bud shape and increased the length of the ducts,
as reported previously (Hoffman et al., 2002). When LY and
SU5402 were combined, the contributions of both inhibitors
were apparent in the resulting morphology (Fig. 6J) in that
the SMG showed elongated irregular ducts typical of the
SU5402 treatment and the large, smooth rounded buds typ-
ical of LY treatment. Quantitation of this experiment (Fig.
6K) again indicated significant differences between the
mean values by ANOVA (P 0.0001). However, there was
an additive effect with LY and SU, and the difference
between LY and LY  SU5402 was significant by Bonfer-
roni’s Multiple Comparison Test (P  0.01). These data
indicate that PI 3-kinase does not appear to be a component
of signaling via FGFR1 during SMG branching morphogen-
esis. However, we cannot rule out the possibility that PI
3-kinase contributes to another signaling pathway involved
in branching morphogenesis in addition to its apparent con-
tribution to EGF-mediated signaling.
Discussion
In this study, we have shown that inhibitors of PI 3-ki-
nase negatively regulate branching morphogenesis in SMG
by acting directly on the epithelium. Consistent with a role
in branching, PI 3-kinase is localized primarily within the
epithelium. We have rescued the effect of the PI 3-kinase
inhibitors by addition of an immediate target of PI 3-kinase,
PIP3. We also report that phosphorylation of Akt, another
Fig. 5. PIP3 stimulates branching in SMG in the presence of LY inhibitor. Eight pairs of E13 glands were treated with media containing 10 M LY  carrier
C1 (A and C) or 10 M LY  C1  PIP3 (B and D). PIP3 stimulated cleft formation in the presence of 10 mM LY (see arrow in high magnification view
in D) relative to a paired gland in (C). (E) Clefts per gland were counted and graphed relative to the number of clefts/gland at time zero and expressed in
AU. Scale bar, 100 m (A, B) and 50 m (C, D).
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downstream effector of PI 3-kinase, decreases (at Ser473)
with increasing incubation time with PI 3-kinase inhibitors
and correlates with inhibition of branching morphogenesis.
Together, these data indicate that PI 3-kinase is involved in
branching morphogenesis and that its effects are mediated
through signaling via PIP3 and possibly Akt. Since the
addition of PIP3 can stimulate cleft formation, we propose a
model in which PIP3-dependent signaling initiates cleft for-
mation. Alternatively, PIP3 may not initiate cleft formation
but may provide a cleft-stabilizing signal. PIP3 is generated
by phosphorylation of PIP2, which also has signal transduc-
tion properties (Czech, 2000). These data suggest that the
formation of PIP3, and not the reduction in PIP2 levels, is
the critical event downstream of PI 3-kinase signaling dur-
ing branching morphogenesis. Since little is known regard-
ing the mechanism of cleft formation, the role of PIP3 in
SMG branching morphogenesis will be the subject of future
studies.
Because the specificity of the chemical inhibitors is a
concern in inhibitor studies (Davies et al., 2000), we have
used two chemically independent PI 3-kinase inhibitors,
LY294002 (LY) and wortmannin (wmn), and observed the
Fig. 6. PI 3-kinase inhibitors have effects on SMG distinct from those of other signaling molecules. After 44 h, compared with control SMG (A), 10 M
LY-treated E13 SMG (B) show fewer and larger rounded buds, while 50 M PD98059-treated SMG (C) show a reduced number of buds. The combination
of 10 M LY and 50 M PD98059 (D) showed no significant difference from LY alone, quantitated in (E). SMG treated with an inhibitor of EGFR signaling,
PD153035 at 50 pM (F), show a decrease in bud number relative to control (A). (G) With the combination of LY (5 M) and PD15035 (50 pM), there is
little difference from LY alone, which can be observed quantitatively (H). (I) SMG treated with 1.5 M SU5402, an inhibitor of FGFR1 signaling, show
elongated stalks and abnormal bud structure. (J) SMG treated with both LY (5 M) and SU5402 (2 M) show a composite morphology reminiscent of both
inhibitors, and an additive inhibitory effect when quantitated (K). Scale bar, 100 m.
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same effects on branching morphogenesis with both. Wmn
has been reported to affect PI4K (Meyers and Cantley,
1997), although not at the levels used in this study. LY has
inhibitory effects on the mammalian target of rapamycin
(mTOR) (Brunn et al., 1996), yet mTOR does not appear to
be a target in SMG branching morphogenesis, since rapa-
mycin itself had no effect on branching (Table 1). LY has
also been reported to inhibit DNA-dependent protein kinase
(Hartley et al., 1995) and casein kinase-2 (CK2) (Davies et
al., 2000). While we found that apigenin, a CK2 inhibitor,
did inhibit branching morphogenesis (Table 1), apigenin is
not specific for CK2 and affects a dozen different kinases
(Pinna, 2002). With the lack of specific CK2 inhibitors, it is
currently difficult to test the role of CK2 in branching
morphogenesis. Nevertheless, as a result of these studies,
we can conclude that PI 3-kinase is involved in branching
morphogenesis; however, we cannot exclude the possibility
of a contributions from other molecules.
PI 3-kinase is a mediator of many signal transduction
pathways in many systems, which include both EGF- and
FGF-stimulated signaling (Carballada et al., 2001; Okano et
al., 2000; Toker, 2000). In agreement with previous data in
which inhibitors of EGFR moderately inhibit branching
morphogenesis (Kashimata and Gresik, 1997; Kashimata et
al., 2000), we have shown that the highly specific EGFR
inhibitor (reported IC50 of 25 pM) inhibits branching mor-
phogenesis in our SMG organ cultures. Likewise, we found
that PD98059 moderately inhibited branching morphogen-
esis (Fig. 6C) similar to previous reports (Kashimata et al.,
2000). In our culture system, not dependent on externally
added growth factors, the effects of the PI 3-kinase inhibitor
LY were greater than the effects of the MAP kinase inhib-
itor PD98059 (Fig. 6E). When LY was combined with
either PD98059 or PD153035, there was no additive effect
in this system. However, when combined with the FGFR1
inhibitor, SU5402, there was a combinatorial effect on
branching morphogenesis, suggesting that LY and SU5402
affect separate pathways. Additional evidence in support of
the hypothesis that PI 3-kinase is not a component of FGF
signaling comes from the results of the mesenchyme-free
cultures. It was previously reported that, in mesenchyme-
free cultures, EGF stimulates bud formation, while FGF7
stimulates duct elongation (Morita and Nogawa, 1999). In
our mesenchyme-free cultures, LY (Fig. 2C) and wmn (Fig.
2D) appear to allow ductal extension but inhibit branching.
Together, these data indicate that PI 3-kinase is a down-
stream effector of EGF, but not FGF, action during SMG
branching morphogenesis.
While the EGFR inhibitor PD153035 is more specific
(Bridges et al., 1996) than the tryophostin RG50864
(Nowak et al., 1997), which was previously used to dem-
onstrate the significance of EGF signaling during SMG
development (Kashimata and Gresik, 1997), it inhibits not
only EGFR1 (ErbB1) but also the EGFR family members
ErbB2, -3, and -4, indicating that one or more of these
family members may be involved in SMG branching mor-
phogenesis. In fact, EGFR1 is not a strong activator of PI
3-kinase (Yarden and Sliwkowski, 2001). Further, it has
been reported that the EGF family member most effective in
stimulating PI 3-kinase activation is ErbB3 (Soltoff et al.,
1994). During SMG branching morphogenesis, it is not
known which ErbB family member simulates PI 3-kinase.
The fact that the inhibitory effects of PI 3-kinase inhib-
itors appear to be greater than that of EGF pathway inhib-
itors indicates that PI 3-kinase may participate in an addi-
tional pathway involved in branching morphogenesis.
Another stimulator of branching morphogenesis is integrin
6, as was shown by the inhibition of branching by integrin
6 inhibitory antibodies in organ culture (Kadoya et al.,
1995), yet the mechanism remains unknown. We added a
function-inhibiting integrin 6 antibody (GoH3) to SMG
cultures and assayed for phosphorylation of Akt at Ser473 as
an indicator of PI 3-kinase activity. However, we found that
there was no effect on Akt phosphorylation by GoH3 (data
not shown), suggesting that PI 3-kinase does not mediate
integrin 6 signaling. The possibility remains that PI 3-ki-
nase contributes to an additional, possibly unknown, path-
way involved in SMG branching morphogenesis.
What additional downstream mediators of PI 3-kinase
might be involved in branching morphogenesis is not
known. Since loss of Akt phosphorylation correlates with
addition of LY and inhibition of branching, Akt may also be
involved. Consistent with this possibility is the fact that
ML-9 inhibits branching morphogenesis at 35 M (data not
shown). Although ML-9 inhibits Akt phosphorylation (Her-
nandez et al., 2001), it is also an inhibitor of myosin-light
chain kinase and protein kinase A at these levels. Rapamy-
cin, besides inhibiting mTOR, also inhibits p70S6 kinase
(p70S6K), which is a downstream mediator of some PI
3-kinase activities. However, since rapamycin did not in-
hibit branching morphogenesis (Table 1), p70S6K does not
appear to play a role in branching morphogenesis. Addi-
tional molecules activated by PI 3-kinase signaling, includ-
ing isoforms of protein kinase C (Nakanishi et al., 1993;
Toker et al., 1994) and Rac (Hawkins et al., 1995), are
potential targets involved in branching morphogenesis. Fu-
ture studies will seek to identify specific molecules down-
stream of PI 3-kinase/PIP3 in branching morphogenesis.
Proliferation, migration, cell-shape change, matrix syn-
thesis, matrix degradation, and other changes in cell phys-
iology are components of the process of branching morpho-
genesis. The processes are different in each branching
organ. In contrast to the kidney, in which branching mor-
phogenesis initiates with ureteric bud outgrowth, branching
initiates with cleft formation in the SMG. It is interesting
that PI 3-kinase plays a role in the initiation of branching in
the kidney and SMG, despite the different mechanisms
involved. In the SMG, it is clear that PI 3-kinase/PIP3 plays
a role in initiation of cleft formation, although it is not clear
whether other physiological mechanisms are involved, ex-
cept that the effects of PI 3-kinase do not appear to depend
on changes in proliferation. In the presence of PI 3-kinase
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inhibitors, proliferation within the epithelium is maintained, as
determined by BrdU incorporation assays (data not shown). It
is not known whether PI 3-kinase can affect some cell migra-
tory processes during SMG cleft formation as it does during
the active cell migration during ureteric bud outgrowth (Tang
et al., 2002). In the future, it will be interesting to identify the
downstream mediators of PI 3-kinase/PIP3 signaling in order to
understand the detailed mechanisms of this pathway during
mouse SMG branching morphogenesis.
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